Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Report 2025

The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size has grown strongly in recent years. It will grow from $8.03 billion in 2024 to $8.6 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing adoption of Pap smear tests, expansion of government-led screening programs, rising prevalence of human papillomavirus (HPV) infections, improved access to women’s healthcare services, greater focus on early detection and precision diagnostics, and the growing number of diagnostic laboratories.

The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size is expected to see strong growth in the next few years. It will grow to $11.18 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the increasing demand for human papillomavirus (HPV) DNA-based testing, greater adoption of self-sampling kits, expansion of healthcare infrastructure in developing countries, heightened focus on personalized medicine, and rising prevalence of cervical intraepithelial neoplasia. Key trends expected in the forecast period include advancements in molecular diagnostic techniques, development of AI-assisted colposcopy tools, innovations in portable screening devices, integration of digital health into cervical diagnostics, introduction of minimally invasive treatment options, and incorporation of cloud-based platforms for diagnostic data management.

The rising prevalence of human papillomavirus (HPV) infections is expected to drive the growth of the cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market. HPV infections are caused by the human papillomavirus, which can affect the skin and mucous membranes and may lead to warts or, in some cases, cervical and other cancers. Early initiation of sexual activity is increasing the risk of HPV exposure at a younger age, contributing to the growing prevalence of infections. Cervical cancer screening, diagnostics, and precancerous lesion treatments help mitigate this burden by enabling early detection and timely intervention, preventing HPV-related cellular abnormalities from progressing to cervical cancer. For example, a March 2025 survey in southern Iran (covering 3,960 cases from July 2021 to July 2023) reported that 1,303 individuals (32.9%) tested HPV positive, with prevalence rising to 36.05% in 2022-2023 compared to 29.92% in 2021-2022. Therefore, increasing HPV prevalence is fueling the growth of the market.

Companies in this space are developing advanced technologies to enhance diagnostic accuracy and early detection. Digital cytology systems, for instance, use high-resolution imaging and artificial intelligence to analyze cervical cell samples, offering faster and more precise results than traditional manual microscopy. In February 2024, Hologic Inc., a US-based health technology company, received FDA clearance for the Genius Digital Diagnostics System. This AI-powered platform improves detection of abnormal cervical cells, increases sensitivity, reduces false negatives, and streamlines workflows by focusing cytologists on targeted cells while supporting remote case reviews.

In March 2024, Halma plc, a UK-based life-saving technology company, acquired Rovers Medical Devices B.V. for $92 million (€85 million) to strengthen its presence in cervical cancer diagnostics. Rovers, based in the Netherlands, develops cell-sampling devices for cervical cancer screening and early detection of precancerous lesions, and the acquisition expands Halma’s women’s health portfolio while supporting global efforts to improve cervical screening rates.

Major players in the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Incorporated, Hologic Inc., bioMérieux S.A., Sysmex Inostics GmbH, Qiagen N.V., BGI Genomics Co. Ltd., CooperSurgical Inc., Fujirebio Holdings Inc., Sansure Biotech Inc., Pregna International Ltd., Arbor Vita Corporation, DYSIS Medical Ltd., Guided Therapeutics Inc., and Femasys Inc.

North America was the largest region in the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in 2024. The regions covered in cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cervical cancer screening, diagnostics, and treatment of precancerous dysplasia lesions encompass the procedures used to detect early signs of cervical cancer, identify abnormal or cancerous cells, and manage precancerous lesions to prevent the progression to cancer. These processes include screening techniques such as Pap smears and human papillomavirus (HPV) testing to assess potential risks, while diagnostic procedures confirm abnormal findings, and treatment focuses on precancerous lesions to stop disease advancement. The primary goal of these interventions is to lower the incidence and mortality of cervical cancer through early detection and management.

The primary categories of cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment are cervical cancer screening, cervical cancer diagnostics, and treatment of precancerous lesions. Cervical cancer screening involves identifying abnormal cervical cells at an early stage before they progress to cancer, using methods such as Pap smears, HPV testing, or visual inspection techniques. These procedures are mainly indicated for cervical intraepithelial neoplasia (CIN) 1 (mild dysplasia), CIN 2 (moderate dysplasia), CIN 3 (severe dysplasia), and invasive cervical cancer. Screening guidelines are organized by age groups: 21-29 years, 30-65 years, and above 65 years, and these services are provided to a range of end users, including hospitals, diagnostic laboratories, specialized gynecology clinics, ambulatory surgical centers, and academic or research institutions.

The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market research report is one of a series of new reports that provides cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market statistics, including cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment industry global market size, regional shares, competitors with a cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market share, detailed cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment industry. This cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market consists of revenues earned by entities by providing services such as Pap smear testing, colposcopy services, biopsy and histopathological analysis, loop electrosurgical excision procedure treatment, and point-of-care cervical screening kits. The market value includes the value of related goods sold by the service provider or included within the service offering. The cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market also includes sales of colposcopy equipment and biopsy tools, liquid-based cytology systems, and visual inspection with acetic acid (VIA) kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.